Objective Peri-implant disease (Mucositis and peri-implantitis) is a major and growing clinical problem in odontology, affecting 20-40mill. patients in Europe, and the double worldwide. Labrida has developed, clinically documented and CE marked a novel,patented (pending) maintenance device for non-surgical management of peri-implant disease. It is a revision brush(“BioClean”), with bioresorbable bristles made of mono-filament chitosan fibres (Patented by Medovent, DE). It offers safer,more effective, less painful and faster treatment of peri-implant disease, where currently the clinical community is in searchfor adequate solutions. The instrument addresses a market in the range of Euro 1-2 billion annual turnover.The device is in small scale production and sold commercially in Scandinavia (TRL 7), with most promising market response.To meet the market opportunity, we will develop up-scaled production processes of advanced chitosan fibres, which iscritical to increase overall production requirements. In addition, we have started development with clinical pilot testing of thenext generation product, comprising chitosan bristles combined with antibiotics, with interesting clinical results. This mayopen a broader application field for deployment of these combinations of materials technologies, both within odontology andwider in medicine.The overall planned project (Phase 2) comprises both industrial development of scaled up production technologies for thechitosan fibres of the currently marketed product , as well as development of the next generation product, combiningadvanced chitosan technologies with bioactive material, e.g. in nanospheres. In phase 1, we intend to refine thedevelopment plan of these product(s) for phase 2, including assessing more in detail the business case, and additionalapplication areas, of the 2nd generation product. Fields of science medical and health sciencesclinical medicinegeneral medicine Programme(s) H2020-EU.2.1.2. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies Main Programme H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument Topic(s) NMP-25-2014-1 - Accelerating the uptake of nanotechnologies, advanced materials or advanced manufacturing and processing technologies by SMEs Call for proposal H2020-SMEInst-2014-2015 See other projects for this call Sub call H2020-SMEINST-1-2014 Funding Scheme SME-1 - SME instrument phase 1 Coordinator LABRIDA AS Net EU contribution € 50 000,00 Address Theodor lovstads vei 32 0286 Oslo Norway See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Norge Oslo og Viken Oslo Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 71 429,00